Summary of key points, looking forward to the official announcement, these seems really positive:
- 40% response rate 5 CR and 1 PR.
- 60% of EMD patients responded, with 20% of AML patients having EMD
- R/R AML and heavily pretreated, Median 4 lines of treatment and 40% >4
- 2 of 5 Bridged to stem cell transplant, 2 with complete remission.
- 3 of 5 Bridged to stem cell transplant, 1 passed due to host rejection, 1 infection and 1 relapse
- Infection of patients with pre-treatment limited patient evaluation.
- Dr Nagler considers it to be IMPRESSIVE and requires further evaluation with Venetoclax
- We know Bisantrene synergises with Venetoclax.
- No Cardiotoxicity observed in treatment.
- Note the board member disclosures who had their hand in the abstract.
Full steam ahead!
ASH2023 - Sheba 2.0, page-4
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
-0.055(3.64%) |
Mkt cap ! $243.3M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.50 | $1.46 | $86.22K | 58.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20 | $1.47 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 188 | 1 |
View Market Depth
| Last trade - 15.58pm 23/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.46 |
Change
-0.055 ( 3.04 %) |
||||
| Open | High | Low | Volume | ||
| $1.46 | $1.50 | $1.46 | 17834 | ||
| Last updated 15.58pm 23/05/2024 ? | |||||
| RAC (ASX) Chart |